Asset profile
LY01008
Monoclonal antibody
Evidence outlook · lead readout
NCT03533127 · Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung...
The completed lead evidence has the design features that historically survive confirmatory trials: randomized, controlled, and adequately powered against a prespecified clinically accepted endpoint.
NCT03533127: This was a randomized, double-blind, active-controlled equivalence trial in 648 patients that measured objective tumor response rate, using the same paclitaxel/carboplatin backbone in both arms. LY01008's response rate was statistically equivalent to bevacizumab's, within the prespecified margin, meeting the trial's own equivalence criterion.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
82 competitors in this universe: 10 direct rivals (same mechanism and indication), 12 same-class, 60 same-indication; 62 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| LY01008: this drug | Phase 3 | Monoclonal antibody | VEGF-A | ||
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | ||
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | ||
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | ||
| Bevacizumab-Awwb (MVASI) | Approved | Monoclonal antibody | VEGF-A | ||
| Jobevne (bevacizumab-Nwgd) | Approved | Monoclonal antibody | VEGF-A | ||
| PF-06439535 | Approved | Monoclonal antibody | VEGF-A | ||
| Vegzelma (bevacizumab-Adcd) | Approved | Monoclonal antibody | VEGF-A | ||
| Zirabev (bevacizumab-Bvzr) | Approved | Monoclonal antibody | VEGF-A | ||
| HD204 | Phase 3 | Monoclonal antibody | VEGF-A | ||
| HLX04 | Phase 3 | Monoclonal antibody | VEGF-A | ||
| Aflibercept (Eylea) | Approved | Protein / enzyme therapeutic | VEGF-A, VEGF-A / VEGF-B / Placental Growth Factor (PlGF) | ||
| Brolucizumab-Dbll | Approved | Monoclonal antibody | VEGF-A | ||
| Pegaptanib (Macugen) | Approved | Small molecule | VEGF-A | ||
| Ranibizumab (Lucentis) | Approved | Monoclonal antibody | VEGF-A | ||
| ABBV-RGX-314 | Phase 3 | Gene therapy / editing | VEGF-A |
…and 67 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
4 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.